

**REMARKS**

The Office Action requires an election under 35 U.S.C. § 121 from among the following groups:

- I. Claims 2-32, drawn to a method for modifying cytokine expression in a cell comprising contacting the cell with a modulator of Notch signalling, wherein the modulator is an activator of Notch signaling, classified in class 435, subclass 7.1;
- II. Claims 2-32, drawn to a method for modifying cytokine expression in a cell comprising contacting the cell with a modulator of Notch signalling, wherein the modulator is an inhibitor of Notch signaling, classified in class 435, subclass 7.1;
- III. Claims 21-25 and 27 drawn to a method for reducing a TH2 or TH1 immune response in a subject comprising administering a cell in which cytokine expression is modified, classified in class 424, subclass 93.7.

Applicants elect Group I, claims 2-32 and claim 1, for further prosecution in this application. Claim 1 links Groups I and II. Under MPEP § 809, Applicants request withdrawal of the restriction between Groups I and II upon allowance of claim 1.

In addition, the Office Action requires a species election. Applicants elect species (a) wherein the modulator is a protein or a polypeptide comprising a Notch ligand DSL domain.

Claims 1 is generic to all species. Applicants understand that, upon the allowance of a generic claim, claims to additional species will be considered, as provided by 37 C.F.R. 1.141. Applicants also understand that the Examiner can broaden the search to include other species, *e.g.*, upon determining that a species is allowable, or when there is a relationship among the species and/or number of species is not too great.

Early action on the merits is earnestly solicited.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP  
Attorneys for Applicants

By: Anne-Marie C. Yvon  
Thomas J. Kowalski  
Reg. No. 32,147

Anne-Marie C. Yvon, Ph.D.  
Reg. No. 52,390  
Tel (212) 588-0800